Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome.
Manish A ShahPeter EnzingerAndrew H KoAllyson J OceanPhilip Agop PhilipPrashant V ThakkarKyle ClevelandYao LuJeremy KortmanskyPaul J ChristosChao ZhangNavjot KaurDina ElmonshedGiuseppe GallettiSandipto SarkarBhavneet BhinderMeredith E PittmanOlga Mikhaylovna PlotnikovaNikita KotlovFelix E FrenkelAlexander V BagaevOlivier ElementoDoron BetelParaskevi GiannakakouHeinz-Josef LenzPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Cabazitaxel has modest activity in advanced gastric cancer, including in patients previously treated with taxanes. Her2 amplification/overexpression and M2 high macrophage signature are potential biomarkers for taxane efficacy that warrant further evaluation.
Keyphrases
- phase ii study
- end stage renal disease
- newly diagnosed
- ejection fraction
- poor prognosis
- chronic kidney disease
- open label
- adipose tissue
- locally advanced
- papillary thyroid
- neoadjuvant chemotherapy
- case report
- squamous cell carcinoma
- cell proliferation
- long non coding rna
- patient reported outcomes
- radiation therapy
- binding protein
- rectal cancer